Deborah Paul

Deborah Paul

Auto-generated profile, based on publicly available information

Deborah Paul

Integrated Hospital Care Institute, Cleveland Clinic

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2025 in Chest
Verified
Journal Article
Closed access
GMGaurav Manek
Gaurav Manek
SZShaoxiong Zhang
Shaoxiong Zhang
EKEduard Krishtopaytis
Eduard Krishtopaytis
APApostolos Perelas
Apostolos Perelas
GKGhaleb Khirfan
Ghaleb Khirfan
ATAdriano R. Tonelli
Adriano R. Tonelli

18 October 2024 in Respiratory Medicine
Verified
Journal Article
Closed access
BBBathmapriya Balakrishnan
Bathmapriya Balakrishnan
JAJehad Azar
Jehad Azar
SFSamar Farha
Samar Farha
AGAlice M. Goyanes
Alice M. Goyanes
JLJames E. Lane
James E. Lane
ATAdriano R. Tonelli
Adriano R. Tonelli

17 February 2026 in Journal of the American Heart Association
Verified
Journal Article
Open access
MSMatthew T. Siuba
Matthew T. Siuba
JLJames Lane
James Lane
VMVaidehi Mendpara
Vaidehi Mendpara
DTDavid Toth
David Toth
DPDeborah Paul
Deborah Paul
ATAdriano R. Tonelli
Adriano R. Tonelli
Background: Accurate cardiac output (CO) measurements during exercise are essential for the diagnosis of exercise pulmonary hypertension (PH), exercise precapillary PH, and exercise postcapillary PH. The purpose of this study is to compare performance of thermodilution CO to gold‐standard direct Fick CO (dfCO) at rest and exercise. Methods: A single‐center prospective cohort study of patients undergoing invasive cardiopulmonary exercise test over a 3‐year period. For the primary outcome, we predicted CO at each stage of exercise and recovery using generalized additive modeling. In secondary analysis, we assessed mean differences in CO across exercise stages and Bland–Altman analysis at rest and peak exercise. Finally, we assessed the impact in classification of exercise PH, exercise precapillary PH, and exercise postcapillary PH between the 2 CO methods. Results: A total of 302 patients were included. In the primary analysis, the generalized additive model smooth term was significantly different between thermodilution and dfCO ( P <0.001), with thermodilution underestimating dfCO at rest and overestimating dfCO at max exercise. Wide limits of agreement were noted between thermodilution and dfCO, particularly at peak exercise (−0.08 (−4.5 to +4.35) L/min). The classification of exercise PH, exercise precapillary PH, and exercise postcapillary PH was not significantly different between CO methods (4, 3, and 1 patient misclassified by thermodilution, respectively). CO reserve using thermodilution was overestimated compared with dfCO (96.66% versus 88.45%, P <0.001). Conclusions: There are differences and wide limits of agreement between thermodilution and dfCO both at rest and during exercise. Sequential measurement of thermodilution during exercise with computing of mPAP/CO and PAWP/CO slopes, reduced the clinical impact of the differences in the diagnosis of exercise PH or exercise postcapillary PH.

28 September 2021
Verified
Book Chapter
Closed access
PDF file
DPDeborah Paul
Deborah Paul
MVMara Weinstein Velez
Mara Weinstein Velez

28 October 2024 in PLOS ONE
Verified
Journal Article
Open access
PDF file
KAKulwant S Aulak
Kulwant S Aulak
LMLori Mavarakis
Lori Mavarakis
LTLiping Tian
Liping Tian
DPDeborah Paul
Deborah Paul
SCSuzy A Comhair
Suzy A Comhair
ATAdriano R Tonelli
Adriano R Tonelli
Pulmonary arterial hypertension (PAH) is a progressive disease characterized by elevated pulmonary arterial pressures that can lead to right heart failure and death. No cure exists for this disease, but therapeutic advancements have extended its median survival from 2 to 7 years. Mechanistic research in PAH has been limited by factors including that a) animal models do not fully recapitulate the disease or provide insights into its pathogenesis, and b) cellular material from PAH patients is primarily obtained from donor lungs during autopsy or transplantation, which reflect end-stage disease. Therefore, there is a need to identify tools that can elucidate the specific mechanisms of human disease in individual patients, a critical step to guide treatment decisions based on specific pathway abnormalities. Here we demonstrate a simple method to isolate and culture circulating endothelial cells (CECs) obtained at the time of right heart catheterization in PAH patients. We tested these CECs using transcriptomics and found that they have typical traits of PAH, including those involving key treatment pathways, i.e. nitric oxide, endothelin, prostacyclin and BMP/activin pathways. CECs show important gene expression changes in other central PAH disease pathways. In summary, we present a new cellular model for the ex-vivo mechanistic evaluation of critical PAH pathways that participate in the pathogenesis of the disease and may help personalized therapeutic decisions.